Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To ?Treat Paroxysmal Nocturnal Hemoglobinuria
Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Nuvectis got permission from China to sell a new medicine called Ciprocopan for a rare blood disease. This is good news because it means the company can now make money in a huge market, which shows their medicine actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.